Sean McClain is the Founder and CEO of Absci, a leading generative AI drug discovery company with a mission to create better biologics for patients, faster. Absci’s platform integrates state-of-the-art generative AI models with proprietary high-throughput wet-lab data to unlock differentiated biology through AI.Sean scaled Absci from a basement lab to a team of 200 employees, raised over $530 million in capital, and forged industry-leading partnerships with companies such as Merck, AstraZeneca, and NVIDIA. He also led the development of an internal pipeline of AI-discovered drug assets, including ABS-101—a potential best-in-class anti-TL1A antibody designed and optimized using generative AI. He holds a Bachelor of Science in Molecular and Cellular Biology from the University of Arizona and serves on the board of Life Science Washington.